PFIZER - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

🧬 Fundamental Stock Analysis: Pfizer India Ltd (PFIZER) Rating: 3.6

🧾 Financial Foundation & Profitability

ROE: 19.8% and ROCE: 27.2% reflect strong capital efficiency, signaling a high-quality business with effective asset utilization.

EPS of ₹100 supports the company’s bottom-line strength.

Debt-to-Equity: 0.00 — the balance sheet is pristine, eliminating interest rate risks and enhancing resilience.

Dividend Yield of 0.66% — offers modest shareholder return, typical for mature, cash-rich firms.

Quarterly profit figures are unavailable, which limits trend visibility — a more detailed earnings breakdown would be key for deeper clarity.

💰 Valuation & Technical Pulse

Metric Value Assessment

P/E Ratio 158 Extremely expensive vs. industry PE of 34.0

P/B Ratio ~17.47 Indicates aggressive market valuation

PEG Ratio Not available Cannot contextualize growth-based valuation

RSI 37.8 Near oversold territory; technical rebound possible

MACD -72.3 Bearish divergence; signals downtrend

Price vs. DMA ₹5,277 vs. DMA50/200: ₹5,353 / ₹4,988 Weak short-term but supported longer-term

Volume Dip: Well below weekly average — may reflect low liquidity or sidelined investor interest.

Institutional Sentiment: FII and DII have mild positive inflows, showing subtle long-term conviction.

🧠 Business Model & Strategic Edge

Profile: Pfizer India is a key pharmaceutical player with strong global branding and a robust portfolio across chronic and acute therapies.

Moat

High trust factor, regulatory excellence, and diversified therapeutic mix.

Innovations from global pipeline can filter into domestic markets.

Limited debt and strong return metrics enhance defensive appeal.

📌 Investment Strategy

Entry Zone Recommendation: Look to accumulate around ₹4,800–₹5,000, near 200-DMA and with better valuation comfort — especially if earnings visibility improves.

Long-Term Guidance

Ideal for conservative investors looking for stability and exposure to pharma.

Monitor for PE compression, earnings consistency, and volume recovery.

Keep tabs on regulatory developments, product launches, and patent shifts.

Would you like a performance comparison with other large-cap pharma players like GSK Pharma or Abbott India? I can chart the differences across valuation, return ratios, and pricing trends to help sharpen your view. Let me know how you'd like to slice it.

Edit in a page